- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | ESMO: Evaxion hopes cancer vax data attracts partner after cash crunch forces smaller ph. 2 trial | 2 | FierceBiotech | ||
| Fr | Evaxion A/S erhöht Grundkapital durch ADS-Verkäufe und Ausübung von Optionsscheinen | 2 | Investing.com Deutsch | ||
| Fr | Evaxion reports 75% response rate in melanoma vaccine trial | 3 | Investing.com | ||
| Fr | Evaxion reports 75% Objective Response Rate in phase 2 trial with AI-designed personalized cancer vaccine EVX-01 | 238 | GlobeNewswire (Europe) | 75% Objective Response Rate as 12 out of 16 advanced melanoma patients had objective clinical responses, with 11 of the 12 responders continuing to respond at 24 months follow-upImmune activation observed... ► Artikel lesen | |
| Di | Evaxion A/S - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| Mo | Evaxion to present a breadth of data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01 at the ESMO Congress 2025 | 309 | GlobeNewswire (Europe) | Presentation will cover two-year clinical efficacy, immunogenicity and safety dataData will be presented at an oral session on October 17, 2025, followed by a webinar on October 22, 2025, providing... ► Artikel lesen | |
| EVAXION Aktie jetzt für 0€ handeln | |||||
| 08.10. | Evaxion expands AI-Immunology platform with automated vaccine design module | 277 | GlobeNewswire (Europe) | New platform module automates previous manual vaccine design processes, improving quality and dramatically reducing time and resource requirementsAI-Immunology, already superior in vaccine target discovery... ► Artikel lesen | |
| 06.10. | Evaxion A/S - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 03.10. | Evaxion to present new biomarker data for AI-designed personalized cancer vaccine EVX-01 at the SITC 2025 Annual Meeting | 329 | GlobeNewswire (Europe) | New biomarker and immune data from the ongoing phase 2 trial with EVX-01 will be presented at the Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting The data will be the latest of many additions... ► Artikel lesen | |
| 25.09. | MSD pays up to nearly $600m for Evaxion's mystery vaccine candidate | 32 | Pharmaceutical Technology | ||
| 25.09. | Evaxion Stock Jumps 27% On Merck Out-Licensing Deal | 19 | RTTNews | ||
| 25.09. | Evaxion Out-licenses Vaccine Candidate EVX-B3 To Merck & Co. | 371 | AFX News | KENILWORTH (NJ) (dpa-AFX) - TechBio company Evaxion A/S (EVAX) announced Thursday it has out-licensed its vaccine candidate EVX-B3 to Merck & Co., Inc. or MSD (MRK), as per the option and license... ► Artikel lesen | |
| 25.09. | Evaxion A/S - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 25.09. | Evaxion out-licenses vaccine candidate EVX-B3 to MSD | 391 | GlobeNewswire (Europe) | MSD exercises its option on vaccine candidate EVX-B3 for a cash payment of $7.5 million, which extend Evaxion's cash runway to first half of 2027 MSD will assume full responsibility for the further... ► Artikel lesen | |
| 25.09. | MSD exercises option on Evaxion's vaccine candidate for $7.5 million | 17 | Investing.com | ||
| 27.08. | Evaxion A/S - 6-K, Report of foreign issuer | 5 | SEC Filings | ||
| 27.08. | Evaxion to present at several conferences during the second half of 2025 | 364 | GlobeNewswire (Europe) | Evaxion will provide scientific and company updates at numerous conferences in both the US, Europe and Asia during the coming months
COPENHAGEN, Denmark, August 27, 2025 - Evaxion A/S (NASDAQ: EVAX)... ► Artikel lesen | |
| 14.08. | Evaxion Biotech ADS GAAP EPS of -$0.02 | 2 | Seeking Alpha | ||
| 14.08. | Evaxion announces business update and second quarter 2025 financial results | 457 | GlobeNewswire (Europe) | COPENHAGEN, Denmark, August 14, 2025 - Evaxion A/S (NASDAQ: EVAX) ("Evaxion"), a clinical-stage TechBio company specializing in developing AI-Immunology powered vaccines, provides business update and... ► Artikel lesen | |
| 13.08. | Insights Ahead: Evaxion Biotech's Quarterly Earnings | 1 | Benzinga.com |
1 2 3 4 Weiter >>
74 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 90,25 | +0,06 % | Diese Biotech-Aktie könnte Big Pharma das Fürchten lehren - mit einem oralen Abnehm-Blockbuster und Milliardenpotenzial bei MS! | Anzeige / WerbungWährend die Aktien von BioNTech und Evotec auf der Stelle treten, befindet sich BioNxt Solutions im Aufwärtstrend. Denn das Unternehmen mischt gerade Big Pharma auf. Die Ankündigung... ► Artikel lesen | |
| EVOTEC | 6,576 | -4,36 % | Alternative zu BioNTec, Evotec und Co.: BioNxt Solutions überzeugt auf Investorenkonferenz und weckt Übernahmefantasie | Während die Aktien von BioNTech und Evotec auf der Stelle treten, befindet sich BioNxt Solutions im Aufwärtstrend. Denn das Unternehmen mischt gerade Big Pharma auf. Die Ankündigung, die Abnehmspritze... ► Artikel lesen | |
| QIAGEN | 41,345 | +0,29 % | QIAGEN N.V. to Release Results for Q3 2025 and Hold Webcast | QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) today announced plans to release results for the third quarter of 2025.
Press release date time: Tuesday, November 4, shortly after 22:05... ► Artikel lesen | |
| CUREVAC | 4,556 | -0,57 % | Erwerb von CureVac durch BioNTech freigegeben | Das Bundeskartellamt hat die geplante Übernahme von bis zu 100 Prozent der Anteile der CureVac N.V. (CureVac), Tübingen, durch die BioNTech SE (BioNTech), Mainz, freigegeben. Der beabsichtigte Erwerb... ► Artikel lesen | |
| PAION | 0,017 | -8,60 % | Interne Dokumente des Wirtschaftsministeriums zeigen: So lief der umstrittene Verkauf der Paion AG an chinesische Investoren ab | ||
| AMGEN | 256,05 | +0,02 % | Amgen And AstraZeneca's TEZSPIRE Approved For Epithelial-Driven Nasal Inflammation | THOUSAND OAKS (dpa-AFX) - Amgen (AMGN) and AstraZeneca announced that the U.S. Food and Drug Administration (FDA) has approved TEZSPIRE (tezepelumab-ekko) as an add-on maintenance treatment... ► Artikel lesen | |
| NOVAVAX | 6,951 | +0,20 % | NOVAVAX INC zündet den Turbo - jetzt wird's brisant! | ||
| STRYKER | 320,80 | 0,00 % | What You Need to Know Ahead of Stryker's Earnings Release | ||
| BIOGEN | 122,10 | -0,33 % | Biogen Inc.: LEQEMBI IQLIK(lecanemab-irmb) Subcutaneous Autoinjector Named to TIME's "Best Inventions of 2025" | TOKYO and CAMBRIDGE, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Headquarters: Cambridge, Massachusetts,... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 59,00 | -0,84 % | CRISPR THERAPEUTICS AG verharrt - jetzt wird's brenzlig! | ||
| CORE ONE LABS | 0,079 | -100,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 22.09.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 22.09.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 22.09.2025ISIN NameAU000000PEK2 PEAK... ► Artikel lesen | |
| OCUGEN | 1,370 | +0,15 % | Ocugen, Inc. and Kwangdong Pharmaceutical Co., Ltd. Complete License Agreement of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea | Upfront fees and near-term development milestone payments totaling up to $7.5 millionPotential sales milestones of $180 million or more in first 10 years of commercializationRoyalties equaling 25%... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 189,99 | +16,77 % | Praxis Precision Medicines prices $525M public offering | ||
| RANI THERAPEUTICS | 1,640 | +248,20 % | Rani Therapeutics Announces up to $1.085 Billion Collaboration with Chugai Pharmaceutical Co. for Multiple High-Value Therapeutics Including Rare Disease and Immunology Programs and Announces Concurrent Oversubscribed $60.3 ... | Rani will receive $10 million upfront payment and is eligible to receive up to $75 million in technology transfer and development milestones, up to $100 million in sales milestones and single digit... ► Artikel lesen | |
| NUVALENT | 92,52 | +2,32 % | Stifel initiates coverage on Nuvalent stock with Buy rating |
Das Unternehmen EVAXION A/S ADR kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell -28,23 % bei einem Aktienkurs von 6,890 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu EVAXION A/S ADR finden Sie auf Wallstreet Online.